摘要
目的分析自拟化瘀涤痰汤联合依达拉奉治疗急性缺血性脑卒中的临床效果及对中医证候评分的影响。方法以2020年1月至12月收治的40例急性缺血性脑卒中患者为研究对象,随机将其分为常规组(20例,依达拉奉治疗)和联合组(20例,自拟化瘀涤痰汤联合依达拉奉治疗)。比较两组的治疗效果。结果联合组的治疗总有效率显著高于常规组(P<0.05)。治疗后,联合组的各项中医证候评分均显著低于常规组(P<0.05)。治疗后,联合组的神经元特异性烯醇化酶(NSE)、S-100B蛋白、缺血修饰蛋白(IMA)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平均显著低于常规组(P<0.05)。治疗后,联合组的全血高切黏度、全血低切黏度、血浆黏度均显著低于常规组(P<0.05)。结论自拟化瘀涤痰汤联合依达拉奉治疗急性缺血性脑卒中可取得理想效果。
Objective To analyze the clinical effect of self-made Huayu Ditan decoction combined with edaravone in the treatment of acute ischemic stroke and its influence on TCM syndrome score.Methods Forty patients with acute ischemic stroke admitted from January to December 2020 were selected as the study objects and randomly divided into conventional group(20 cases,edaravone treatment)and combined group(20 cases,self-made Huayu Ditan decoction combined with edaravone treatment).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the combined group was significantly higher than that in the conventional group(P<0.05).After treatment,the TCM syndrome scores of the combined group were significantly lower than those of the conventional group(P<0.05).After treatment,the levels of neuron-specific enolase(NSE),S-100B protein,ischemia modified albumin(IMA),tumor necrosis factor-α(TNF-α)and interleukin-1β(IL-1β)in the combined group were significantly lower than those in the conventional group(P<0.05).After treatment,whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity in the combined group were significantly lower than those in the conventional group(P<0.05).Conclusion The self-made Huayu Ditan decoction combined with edaravone in the treatment of acute ischemic stroke can achieve ideal effect.
作者
齐爱军
景永刚
高俊丽
QI Aijun;JING Yonggang;GAO Junli(Shaanxi Second Provincial People's Hospital,Xi'an 710005;Binzhou People's Hospital of Shaanxi Province,Xianyang 713500;Hanzhong Central Hospital,Hanzhong 723000,China)
出处
《临床医学研究与实践》
2024年第4期122-125,共4页
Clinical Research and Practice
基金
陕西省卫生健康科研基金项目(No.2021B002)。
